tapebrief
IQV · Q4 2025

IQV · Q1 2026 Earnings

Bullish

IQVIA

Reported May 5, 2026

30-second summary

IQVIA beat its own Q1 guide across revenue ($4.151B, +8.4% YoY), non-GAAP EPS ($2.90 vs. $2.77–2.87 guide), and EBITDA ($932M, upper-middle of $920–940M), and the demand metrics under the hood were stronger than the headline: organic growth doubled in Commercial Solutions and tripled in RDS year-over-year, with R&DS book-to-bill at 1.04x (TTM 1.11x) and backlog at a record $34.2B. Management raised FY26 EPS by $0.10 at both ends to $12.65–12.95 but explicitly reaffirmed FY revenue ($17.15–17.35B) and EBITDA ($3,975–4,025M) — a hedge that says "Q1 was clean, but we're not extrapolating yet," consistent with the +6.5–8.0% Q2 revenue guide that implies a step-up from Q1's pace.

Headline numbers

EPS

Q1 FY2026

$2.90

Revenue

Q1 FY2026

$4.15B

+8.4% YoY

Gross margin

Q1 FY2026

32.6%

Free cash flow

Q1 FY2026

$0.49B

Operating margin

Q1 FY2026

12.4%

Key financials

Q1 FY2026
MetricQ1 FY2026YoYQ4 FY2025QoQ
Revenue$4.15B+8.4%$4.36B-4.9%
EPS$2.90—$3.42-15.2%
Gross margin32.6%—32.9%-30bps
Operating margin12.4%—14.4%-200bps
Free cash flow$0.49B—$0.56B-12.5%

Guidance

IQVIA raised full-year FY2026 adjusted diluted EPS guidance by $0.10 at both low and high ends to $12.65–$12.95 following a strong Q1 beat on revenue, EPS, and EBITDA, while reaffirming revenue and Adjusted EBITDA; Q2 FY2026 guidance introduced with mid-single-digit YoY growth expectations.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
RevenueQ1 FY2026$4.05B to $4.15B$4.151B+0.001B above high endBeat
Adjusted Diluted EPSQ1 FY2026$2.77 to $2.87$2.90+0.03 above high endBeat
Adjusted EBITDAQ1 FY2026$920M to $940M$932Min-lineBeat

New guidance

MetricPeriodGuideYoY
RevenueQ2 FY2026$4.28B to $4.34B+6.5% to +8.0% YoY
Adjusted Diluted EPSQ2 FY2026$2.98 to $3.08+6.0% to +9.6% YoY
Adjusted EBITDAQ2 FY2026$955M to $975M+4.9% to +7.1% YoY

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Adjusted Diluted EPS
FY2026
$12.55 to $12.85$12.65 to $12.95+0.10 at low end, +0.10 at high endRaised

Reaffirmed unchanged this quarter: Revenue ($17.15B to $17.35B), Adjusted EBITDA ($3,975M to $4,025M)

Segment KPIs

Q1 FY2026
SegmentQ1 FY2026YoY
Commercial Solutions$1.754B+11.6%
Research & Development Solutions$2.397B+6.2%

Other KPIs

Q1 FY2026
SegmentQ1 FY2026
R&D Solutions Contracted Backlog$34.2 billion
R&D Solutions Net New Bookings$2.5 billion
Book-to-Bill Ratio1.04x
Trailing Twelve-Month Book-to-Bill Ratio1.11x
R&D Solutions Expected Backlog Conversion (12 months)$8.9 billion
Expected Backlog Conversion Growth YoY7.6%
Adjusted EBITDA$932 million
Net Leverage Ratio3.62x

Management tone

Q2 "see more, win more" → Q3 demand acceleration → Q4 confident reframe with structural simplification → Q1 FY26 AI-native operating model with organic growth doubled/tripled.

The AI narrative completed its transition from capability story to operating identity. In Q2 FY25 management disclosed 20+ agents in production with productivity anecdotes; Q3 raised that to 90 agents in development with a 500-agent 2027 target; Q4 anchored AI to "top 20 pharma" multi-year enterprise commitments. This quarter the verbatim is "We already function as an AI native company in life sciences," with 192 agents deployed, 64 use cases, and 19 of the top 20 pharma using IQVIA agents in their workflows. The "AI-native" framing is a deliberate competitive-moat assertion — management is no longer arguing IQVIA is adopting AI, they're arguing IQVIA is the AI substrate for life sciences. The risk is that this language gets reverse-tested if any single top-20 pharma builds in-house agentic capability and walks away.

The demand commentary went from "stabilized" to "accelerating." Q4 management called the environment "stabilized somewhat and demand indicators became more favorable." This quarter it's "outstanding start to the year, with organic revenue growth accelerating more than anticipated," with EVP funding nearly doubling YoY in Q1. In the Stifel Q&A, management framed large pharma as "explicitly stating intention to double pipeline molecules and asking about CRO capacity expansion" — a forward demand signal that goes beyond cyclical recovery into structural pipeline replenishment driven by AI-enabled discovery. If true, this re-rates the 2027+ CRO demand curve materially.

Margin defense pivoted from cyclical-to-mix-managed (Q4) to operational-strength-masked-by-accounting (Q1). Q4 framed pass-through moderation as a 2026 EBITDA margin headwind to be absorbed. This quarter management owns that the margin optics will look ugly when pass-throughs drop but explicitly says operational margins expanded — a more confident posture. The Deutsche Bank Q&A: "Q1 EBITDA margin contraction entirely from non-operational headwinds." The bull case requires this framing to hold across the year. If Q2 EBITDA margin (implied ~22.5% at midpoint of $965M / $4.31B) compresses further, the "operational strength masked by accounting" narrative gets harder to defend.

Forward guidance discipline became more conservative even as confidence rose. This is the tension worth naming. Management language is the most bullish in the disclosed sequence ("outstanding start," "accelerating more than anticipated," "AI-native"), yet they raised FY EPS by $0.10 against a $0.03 Q1 beat and held revenue/EBITDA flat. A confident management team beating on every line typically flows more through to the FY. The restraint suggests either (a) deliberate sandbagging to set up clean Q2–Q4 prints, or (b) specific concerns about Q3/Q4 visibility — likely pass-through normalization timing or FX volatility — that management chose not to disclose explicitly.

Recurring themes management leaned on this quarter:

AI agents deployment scale and adoption (192 agents, 64 use cases, 19 of top 20 pharmas)Organic growth acceleration (commercial doubled, RMDS tripled YoY)Record backlog and forward-looking demand metricsAI-ready data foundations as client value driverMargin expansion through AI-enabled operational efficiencyStrategic partnerships consolidating IQVIA's market position

Risks management surfaced:

Foreign exchange headwinds (though currently assumed to remain flat through 2026)Pass-through bookings volatility impacting book-to-bill ratioMix of full-service versus pass-through trials affecting near-term metrics

Q&A highlights

Michael Tierney · Lerink Partners

How should we think about the conversion of service versus pass-through bookings won in the quarter, and what is the margin progression impact, especially for full-service oriented wins in R&DS?

Pass-throughs have zero profitability impact and are irrelevant to margin analysis. Q1 pass-throughs were one-third below historic average due to trial mix, not a strategic shift. Service fee bookings were up significantly year-over-year and sequentially. Book-to-bill ratio is a poor predictor of future growth; company uses conservative booking policy (contracts only). No AI impact on bookings or competitive losses.

$2.5 billion in trial bookings in Q1Pass-throughs one-third below historic averageQ1 sequential net new bookings down 13% (vs. typical 16-17%)Book-to-bill of 1.02 last year predicted current 3% organic R&DS growth poorly

Justin Bowers · Deutsche Bank

Are full-service trial dynamics reflecting a shift in customer clinical strategy or large pharma behavior? When should we expect margin benefits from lower pass-throughs?

One quarter of bookings does not indicate a trend; pass-through levels are cyclical and mix-dependent, not indicative of customer behavior changes. Margin impact immaterial; bookings burn over 5 years. Operationally, Q1 showed significant EBITDA margin expansion despite adverse portfolio mix due to strong productivity programs. Demand environment is constructive with no fundamental changes in outsourcing drivers.

No correlation between one quarter bookings and future marginsQ1 EBITDA margin contraction entirely from non-operational headwinds (pass-throughs)Operational margins expanded significantly in Q1 despite adverse mixPass-through impact is accounting requirement, not profitability driver

Luke Sergot · Barclays

Which commercial solutions businesses were most surprising, and what is the mix of recurring versus discretionary revenue?

Commercial Solutions grew 5% organically (11.6% reported), double YoY growth. Growth driven by AI creating new demand, not replacing services. Record pipelines in analytics/consulting; health-grade AI agents creating competitive differentiation. Info business ~30% of total growing low single digits; patient solutions in double digits; analytics/consulting/commercial tech/engagement growing mid-to-high single digits. New drug launches doubled (10 vs. 6-7 YoY).

Commercial Solutions organic growth: 5% (vs. 2.5% YoY)Reported growth 11.6%; constant currency 8.5%10 new drug launches in Q1 vs. 6-7 prior yearInfo business: ~30% of total, low single digit growth

Shlomo Rosenbaum · Stifle

Where is the market actually accelerating versus just stabilizing? Are gains from market growth or improved win rates?

Market is stabilizing and improving but not yet back to pre-disruption levels. Large pharma is more constructive but still deliberate in capital deployment. EVP funding at record $20B in Q1 (nearly 2x YoY), indicating renewed confidence. AI discovery tools increasing molecule identification, which will increase trial demand. Large pharma explicitly stating intention to double pipeline molecules and asking about CRO capacity expansion. Company beat all financial metrics; margins expanding operationally.

EVP funding: $20B in Q1 (vs. ~$10B prior year)Large pharma planning to double molecules in pipeline using AI90%+ of AI adoption at discovery stage, not clinical executionComing out of 3-4 years of policy-driven headwinds

Eric Coldwell · Baird

Can you validate math on adjusted book-to-bill accounting for normalized pass-through mix (~1.15x if normalized)? Can you provide constant currency organic growth rates for both segments?

Management confirms analyst's math approach is correct: if pass-throughs were at normalized 30% levels instead of Q1's depressed levels, book-to-bill would be approximately 1.15x rather than reported levels. Provides organic growth reconciliation: R&DS reported 6.2% (2 pts FX, 1 pt acquisitions = 3% organic; prior year 1% organic). Commercial reported 11.5% (3 pts FX, 3+ pts acquisitions = 5% organic). Enterprise organic: 4%.

R&DS organic growth Q1: 3% (vs. 1% prior year)Commercial organic growth Q1: 5% (implied prior year ~2.5%)Enterprise organic growth: 4%Normalized book-to-bill ~1.15x (adjusted for pass-through normalization)

Answers to last quarter's watch list

Q1 FY26 revenue landing within the ~$4.05–4.15B guide. Revenue printed $4.151B — $1M above the high end. Beat, though by a narrow margin in absolute dollar terms; the more important signal is +8.4% YoY accelerating from FY25's +5.9% delivered. FY26 +5–6% framing remains intact, with management implicitly running ahead of it. Status: Resolved positively.
EBITDA margin trajectory under new segment reporting. Q1 EBITDA margin printed 22.5% — below the high-22%-to-low-23% range expected from pass-through moderation. Management attributes the gap entirely to pass-through compression with operational margins expanding. The metric came in below expectations but for the reason management telegraphed; the question now is whether Q2 holds at ~22.5% or moves lower. Status: Resolved negatively on the optic, Continue monitoring on whether the operational story holds.
RDS book-to-bill sustaining ≥1.10x under new segment structure. Q1 standalone printed 1.04x, below the 1.10x threshold. TTM at 1.11x just barely holds. Management's explanation — pass-through mix compressed the denominator — is operationally credible and validated by service-fee booking growth, but the standalone number breached the threshold flagged last quarter. Status: Resolved negatively on the literal metric, with the caveat that the underlying booking quality (service fees double-digit YoY) tells a better story.
Organic Commercial Solutions growth ex-Cedargate. Management disclosed organic at ~5% (vs. ~2.5% prior year), with reported growth bridge of FX +3pts, acquisitions +3pts. This is the disclosure last quarter's watch item asked for, and it validates the FY26 +7–9% Commercial Solutions guide as plausibly attainable as the organic rate continues to accelerate. Status: Resolved positively.
AI revenue contribution as a disclosed line. Management gave the most detailed AI deployment metrics yet (192 agents, 64 use cases, 19 of top 20 pharma using IQVIA agents) but still did not quantify AI-specific revenue. The "AI-native" framing increases the disclosure pressure further. The story remains operational, not financial. Status: Continue monitoring.
Net interest expense holding at ~$760M / net leverage trajectory. Net leverage at 3.62x vs. Q4's 3.63x — essentially flat. Net interest expense wasn't called out in this print's available disclosure. With the FY26 ~$760M figure issued last quarter not reiterated, the visibility on this line item has actually decreased. Buyback cadence in Q1 was $552M, with $1.2B of repo authorization remaining. Status: Continue monitoring, with reduced disclosure transparency on the interest line.

What to watch into next quarter

Q2 revenue landing within the $4.28–4.34B guide (implies +6.5–8.0% YoY against the $4.02B Q2 FY25 base). Midpoint $4.31B implies +7.3% YoY — a deceleration from Q1's +8.4% but on a tougher base. A print at the high end (~$4.34B, +8.0%) keeps the FY revenue raise narrative alive; a low-end print (~$4.28B) validates management's reaffirmed-not-raised posture.

EBITDA margin holding at or above Q1's 22.5%. Q2 guide of $955–975M against $4.28–4.34B revenue implies EBITDA margin of ~22.3% at the low end, ~22.5% at midpoint. If Q2 prints below 22%, the "operational margin expanding, masked by pass-throughs" narrative needs a more concrete defense.

R&DS book-to-bill standalone returning to ≥1.10x. Q1's 1.04x was explained by pass-through mix; Q2 needs to validate that explanation. A second consecutive sub-1.10x print would shift the booking-quality concern from accounting noise to structural.

Whether segment-level FY26 guides (Commercial $7.2–7.3B, RDS $9.9–10.0B) reappear in disclosure. Their absence this quarter is noted but not yet alarming. Continued non-reiteration through Q2 would be a meaningful reduction in transparency given the new two-segment structure was supposed to improve clarity.

AI revenue attribution as a disclosed dollar figure. Four quarters of agent counts without revenue numbers, now with "AI-native" framing applied. The next credible disclosure escalation is dollar contribution. If Q2 still defers, sell-side will start to model the absence as a gap.

EVP funding sustaining at or above the Q1 pace. Management cited Q1 EVP funding nearly doubling YoY as a forward demand signal. A meaningful Q2 step-down would undercut the "structural acceleration" narrative and revert the story to cyclical-only.

Sources

  1. IQVIA Q1 2026 earnings press release (SEC filing): https://www.sec.gov/Archives/edgar/data/1478242/000162828026030118/iqv-q1x2026earningspressre.htm
  2. IQVIA Q1 2026 earnings call commentary (referenced in transcript-derived guidance and Q&A extracts)
  3. Tapebrief IQV Q4 2025 brief (prior-quarter watch list, FY26 guidance baseline, segment trends)
  4. Tapebrief IQV Q3 2025 brief (multi-quarter tone arc and demand-acceleration trajectory)
  5. Tapebrief IQV Q2 2025 brief (AI deployment baseline and margin compression decomposition)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.